Literature DB >> 23486271

Rapid response of brain metastasis to crizotinib in a patient with ALK rearrangement-positive non-small-cell lung cancer.

Hiroyasu Kaneda1, Isamu Okamoto, Kazuhiko Nakagawa.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23486271     DOI： 10.1097/JTO.0b013e3182843771

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN： 1556-0864            Impact factor:   15.609


× No keyword cloud information.
  22 in total

1.  Long-lasting response to crizotinib in brain metastases due to EML4-ALK-rearranged non-small-cell lung cancer.

Authors:  Yoshiaki Kinoshita; Yasutaka Koga; Atsuhiko Sakamoto; Kouko Hidaka
Journal:  BMJ Case Rep       Date:  2013-09-10

Review 2.  Targeted therapy combined with radiotherapy in non-small-cell lung cancer: a review of the Oncologic Group for the Study of Lung Cancer (Spanish Radiation Oncology Society).

Authors:  F Couñago; A Rodríguez; P Calvo; J Luna; J L Monroy; B Taboada; V Díaz; N Rodríguez de Dios
Journal:  Clin Transl Oncol       Date:  2016-04-22       Impact factor: 3.405

Review 3.  Tackling ALK in non-small cell lung cancer: the role of novel inhibitors.

Authors:  Francesco Facchinetti; Marcello Tiseo; Massimo Di Maio; Paolo Graziano; Emilio Bria; Giulio Rossi; Silvia Novello
Journal:  Transl Lung Cancer Res       Date:  2016-06

4.  PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical Models.

Authors:  Helen Y Zou; Luc Friboulet; David P Kodack; Lars D Engstrom; Qiuhua Li; Melissa West; Ruth W Tang; Hui Wang; Konstantinos Tsaparikos; Jinwei Wang; Sergei Timofeevski; Ryohei Katayama; Dac M Dinh; Hieu Lam; Justine L Lam; Shinji Yamazaki; Wenyue Hu; Bhushankumar Patel; Divya Bezwada; Rosa L Frias; Eugene Lifshits; Sidra Mahmood; Justin F Gainor; Timothy Affolter; Patrick B Lappin; Hovhannes Gukasyan; Nathan Lee; Shibing Deng; Rakesh K Jain; Ted W Johnson; Alice T Shaw; Valeria R Fantin; Tod Smeal
Journal:  Cancer Cell       Date:  2015-07-02       Impact factor: 31.743

5.  Significance of targeted therapy and genetic alterations in EGFR, ALK, or KRAS on survival in patients with non-small cell lung cancer treated with radiotherapy for brain metastases.

Authors:  Kimberley S Mak; Justin F Gainor; Andrzej Niemierko; Kevin S Oh; Henning Willers; Noah C Choi; Jay S Loeffler; Lecia V Sequist; Alice T Shaw; Helen A Shih
Journal:  Neuro Oncol       Date:  2014-07-22       Impact factor: 12.300

Review 6.  Brain metastases in non-small-cell lung cancer: better outcomes through current therapies and utilization of molecularly targeted approaches.

Authors:  Rimas V Lukas; Maciej S Lesniak; Ravi Salgia
Journal:  CNS Oncol       Date:  2014-01

Review 7.  Oral Targeted Therapies and Central Nervous System (CNS) Metastases.

Authors:  Michael P Gabay; Scott M Wirth; Joan M Stachnik; Colleen L Overley; Katie E Long; Linda R Bressler; John L Villano
Journal:  CNS Drugs       Date:  2015-11       Impact factor: 5.749

Review 8.  Treatment Optimization for Brain Metastasis from Anaplastic Lymphoma Kinase Rearrangement Non-Small-Cell Lung Cancer.

Authors:  Wenhui Wang; Xin Sun; Zhouguang Hui
Journal:  Oncol Res Treat       Date:  2019-09-17       Impact factor: 2.825

Review 9.  Insights into brain metastasis in patients with ALK+ lung cancer: is the brain truly a sanctuary?

Authors:  Gouji Toyokawa; Takashi Seto; Mitsuhiro Takenoyama; Yukito Ichinose
Journal:  Cancer Metastasis Rev       Date:  2015-12       Impact factor: 9.264

Review 10.  A Systemic Review of Resistance Mechanisms and Ongoing Clinical Trials in ALK-Rearranged Non-Small Cell Lung Cancer.

Authors:  Khashayar Esfahani; Jason Scott Agulnik; Victor Cohen
Journal:  Front Oncol       Date:  2014-07-21       Impact factor: 6.244
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.